Shots:
- EpiBiologics has dosed the first patient in a global P-I study evaluating EPI-326, a tissue-selective bispecific antibody targeting EGFR, in advanced solid tumors
- The first-in-human study will assess safety, tolerability, PK, and preliminary anti-tumor activity in pts with NSCLC and HNSCC, with potential expansion into colorectal cancer
- Preclinical data showed robust anti-tumor activity across EGFR-mutant and wild-type models, favorable tolerability without typical EGFR toxicities, and potential for combination with TKIs and KRAS inhibitors
Ref: Business Wire | Image: EpiBiologics | Press Release
Related News: Earendil Labs Doses First Patient with HXN-1001 in P-IIa Trial in Ulcerative Colitis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
